EES-Web Receipt date: 09/29/2006

BARNES & THORNBURG LLP

10/594791 IAPO1 Rec'd PCT/PTO 29 SEP 2006

> 11 South Meridian Street Indianapolis, Indiana 46204 (317) 236-1313 (317) 231-7433 Fax

## IN THE UNITED STATES PATENT OFFICE

Earliest Priority	2 April 2004 (02.04.2004)	Certificate Under 37 CFR 1.10
Date:		Express Mail No.: <u>EV 417142613 US</u>
International	PCT/GB2005/001197	Date of Mailing: 29 September 2006
Serial No.:		I hereby certify that this correspondence is being deposited with the United States Postal Service's
U.S. Serial No.:	Unknown	<ul> <li>"Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date above and is addressed to the Commissioner for Patents, P.O. Bo 1450, Alexandria, VA. 22313-1450.</li> </ul>
Invention:	CANCER ASSOCIATED ANTIGENS	Signature)
Applicants:	REES, Robert Charles; MILES, Amanda Kathleen; LI, Geng	Ernest A. Carlson (Typed or Printed Name of Person Mailing Paper or Fee)
International Filing Date:	24 March 2005 (24.03.2005)	}
Attorney	42133-200861	,

## INFORMATION DISCLOSURE STATEMENT

Attn: DO/EO/US Mail Stop: PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Docket:

This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.56. In accordance with 37 C.F.R. § 1.98(a)(2), no copies of the cited U.S. references are provided. A copy of each of the other references is provided for review by the Examiner.

No representation is intended that a complete search has been made of the prior art or that no better art references than those listed below are available. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

EES-Web Receipt date: 09/29/2006

## 10/594791 IAPO1 Rec'd PCT/PTO 29 SEP 2006

Please charge any fees that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 10-0435, using our reference number 42133-200861. A duplicate copy of this authorization is enclosed for that purpose.

Respectfully submitted,

Keyin L. McLaren Atty. Reg. No. 48351 Attorney for Applicants

KLM/ezc/838193 Indianapolis, Indiana 46204 (317) 231-7776

£8-We	6 Re	ניקוע איז ceipt da	te: 09/2	§/2006
-------	------	-----------------------	----------	--------

	•	_	n		<b>' 5</b>	$\mathbf{\cap}$	
Sheet	_1		U	/	フ	7	

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

42133-200861

IAPOT REE'T PCT/PTO

Unknown

INFORMATION	DISCLOSURE	STATEMENT	

APPLICANT REES, Robert Charles et al.

FILING DATE

GROUP

Herewith UNKNOWN

U.S. PATEN	T DOCU	MENTS					
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA		<u></u>				
FOREIGN F	ATENT D	OCUMENTS					
		Document Number	Date	Country	Class	Subclass	Translation Yes No
/BD/	АВ	WO2001/053312 A1	7/26/2001	wo			
OTHER REI	ERENCE	S (Including Author, Title, D	ate, Pertinent Pages,	Etc.)			
/BD/	AC	Simplex Virus (HSV) Vect	or, DISC/HSV/Murine	ed by Intratumor Therapy with a Granulocyte-Macrophage Colonunology, 2002, Vol. 168, pp. 3.	ny-Stimulatir	ectious Single ng Factor, Corr	Cycle (DISC) Herpes relates with Antigen-
<b></b>	AD	CHEN Voc Toons at al. 5	'A tasticular antique ab	errantly expressed in human car			
77000000		The National Academy of	Sciences of the USA, 1	997, Vol. 94, pp. 1914-1918		by autologous	s antibody screening,"
	AE	GOEPEL, J.R., et al., "Los Cancer, 1991, Vol. 64, pp.		polymorphic HLA antigens in n	netastatic bre	ast and colon c	arcinoma," Br. J.
000000000000000000000000000000000000000	AF			ING1 Tumor Supressor Gene P pts and a Homologue Gene," Ca			
35500000000	AG	JAGER, Elke, et al., "Induce patients with NY-ESO-1+	ction of primary NY-ES cancers," PNAS, 2000,	SO-1 immunity: CD8+T lymph Vol. 97 No. 22, pp. 12198-1220	ocyte and ant	ibody response	es in peptide-vaccinated
***************************************	АН	JAGER, Elke, et al., "Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral cellular immune responses," PNAS, 2000, Vol. 97, No. 9, pp. 4760-4765					
2000	AI	McINTYRE, Catherine A., et al., "Treatment of Malignant Melanoma and Renal Cell Carcinoma with Recombinant Human Interleukin-2: Analysis of Cytokine Levels in Sera and Culture Supernatants," Eu F. Cancer, 1992, Vol. 28, No. 1, pp 58-63					
80	AJ	MIAN, Shahid, et al., "Imn	nunogenicity of tumor	associated antigens, Cancer Imn	nunology," 20	001, pp. 1-26	
	AK	OLD, R. W., et al., "Princip	ples of Gene Manipulat	ion, An Introduction to Genetic	Engineering,	" 5 <sup>th</sup> Edition, 1	994, Fig. 10.1
	AL	SAHIN, Ugur, et al., "Hum USA, 1995, Vol. 92, pp. 11	an neoplasms elicit mu 810-11813	ltiple specific immune response	s in the autol	ogous host," P	roc. Natl. Acad. Sci.
000000000000000000000000000000000000000	AM	SCANLAN, Matthew J., et al., "CHARACTERIZATION OF HUMAN COLON CANCER ANTIGENS RECOGNIZED BY AUTOLOGOUS ANTIBODIES," Int. J. Cancer, 1998, Vol. 76, pp. 652-658					
300000000000000000000000000000000000000	AN	STOCKERT, E., et al., "A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens," J. Exp. Med., 1998, Vol., No. 8, pp. 1349-1354					
2000000	AO	THOMSON, Scott A., et al., "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," The Journal of Immunology, 1998, Vol. 160, pp. 1717-1723					
000	АР	TURECI, Ozlem, et al., "Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease," The Journal Of Biological Chemistry, 1997, Vol. 272, No. 10, pp. 6416-6422					
000000000000000000000000000000000000000	AQ			logy 8: Tumor Antigens, Expre eedings of the American Associa			
	AR	XP-002336236, LEE, Sang	-Yull, et al., "Immunon	nic analysis of human sarcoma,'	'PNAS, 2003	3, Vol. 100, No	o. 5, pp. 2651-2656
V	AS XP-002336237, Lee, et al., "Table 3 Sarcoma/Testes antigens defined by serological analysis of cDNA expression libraries," Proc. Nat'l. Acad. Sci., 2003, Vol. 10, 0437972100					sion libraries," Proc.	
*EXAMINER	Initial if	reference considered, whethe	r or not citation is in co	enformance with MPFP 600			
Draw line thro	ugh citatio	on if not in conformance and	not considered. Include	e copy of this form with next co	mmunication	to applicant.	

EFSeweb Heceipt date: 09/29/2006

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Unknown

42133-200861

APPLICANT REES, Robert Charles et al. FILING DATE

GROUP

Herewith

UNKNOWN

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	ВА					ļ	
FOREIGN PA	TENT D	OCUMENTS	· · · · · · · · · · · · · · · · · · ·				
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	вв						
OTHER REF	RENCE	S (Including Author, Title, D	ate, Pertinent Pages, I	Etc.)			
/BD/	вс	VD 002336240 1 EE S V	et al Accession No	AV311015Hemo-capione-care	omo ontigan	NIV CAR 22	DNA mortial adal?
8	ВС				-		
000000000000000000000000000000000000000	BD	XP-002336241, OTA, T., s similar to splicing factor, A	ACDUNE/SERPIE R	(While Dentillania espiene espiene espiene Children	-FLJ10330-6	is-elene-NT2R	M2000624-weekly
	BE	<del>\{}\@\@@@@@@@@\\\\\\\\\\\\\\\\\\\\\\\\\</del>	T., er al., Accession to	. 773139197, Human potynucio	onde SEQ. 1	D: NO: 1400"	
	DE						
<del></del>	BF	XP-002336283, TANG, Y.	1., Accession No. AAN	140041, Human polypepiide 9	EQ: ID: IVO:	2466	
	BG		<u> </u>	··· <del>^</del>	RF2399 poly	peptide sequei	rcc 5EQ. 1D. 140. 4798*
<del>                                     </del>	ВН	->tP-002336286;-OT-1-;-T-;a	talijihaaassiam NamAi	(876100, "Sequence 11104 from	- Patent EP1	074617"	
	70.7	VD 002226287 CHCAHA	DA T	N. ADI2006 "II		CTAT(	
	ві	344.005333561,356014454	Ichtionbiochaltiobateccaalou	<del>designed History &amp; Sold Marketter for the following the f</del>	mana promo		obess of the state
*	BJ	M 902336288, HONDA 6	i,, et al., Accession No.	DD587825, "STAT6 activating	oo Book de gegenoor		
	BK						
	BL						
	BM						
	DIVI						
	BN						<b></b>
,					-		-
	ВО						
	ВР						
	_						
	BQ			<u>.</u>			
	BR	<del>                                     </del>					
	_						
	BS					<del></del>	
	D.T.						
	вт						
+=====================================		/Brad Du	iffy/		-		06/06/2008
TEXAMINER: Draw line throu	initial if	reference considered, whether on if not in conformance and	r or not citation is in co not considered. Include	onformance with MPEP 609.  e copy of this form with next co	mmunication	to applicant.	